Previous close | 27.83 |
Open | 28.13 |
Bid | 28.07 x 500 |
Ask | 28.12 x 500 |
Day's range | 27.55 - 28.28 |
52-week range | 12.75 - 44.32 |
Volume | |
Avg. volume | 1,696,385 |
Market cap | 5.256B |
Beta (5Y monthly) | 1.03 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.26 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 49.67 |
The latest analyst coverage could presage a bad day for BridgeBio Pharma, Inc. ( NASDAQ:BBIO ), with the analysts...
BridgeBio Pharma ( NASDAQ:BBIO ) First Quarter 2024 Results Key Financial Results Revenue: US$211.1m (up by US$209.3m...
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abst